Actinium Pharmaceuticals Appoints Sean Maenpaa as Business Development Lead
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) has appointed Sean Maenpaa as Senior Vice President of Business Development, effective October 12, 2026. Maenpaa brings more than two decades of commercial and business development experience in oncology and radiopharmaceuticals to the role.
In his new position, Maenpaa will lead Actinium's corporate development strategy, overseeing licensing, out-licensing, strategic partnerships, and corporate transactions across the company's targeted radiotherapy pipeline. His background spans isotope supply, diagnostic imaging, and therapeutic radiopharmaceuticals. Prior to joining Actinium, he held leadership roles at BWXT Medical, Telix Pharmaceuticals, Clovis Oncology, Bayer AG, Novartis, and Celgene.
The executive appointment comes as large pharmaceutical companies show increasing strategic interest in targeted radiotherapies. Investors will watch how Maenpaa leverages his industry relationships to secure corporate partnerships and commercialization deals for Actinium's oncology assets, including its lead programs in hematology and solid tumors.
Key points
- Actinium Pharmaceuticals appointed Sean Maenpaa as Senior Vice President of Business Development, effective October 12, 2026.
- Maenpaa brings over 20 years of experience in oncology business development, commercial strategy, and radiopharmaceutical management.
- He will oversee licensing, out-licensing, corporate partnering, and strategic transactions across Actinium's radiotherapy pipeline.
- His previous background includes leadership roles at BWXT Medical, Telix Pharmaceuticals, Clovis Oncology, Bayer AG, Novartis, and Celgene.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
Who is the new Business Development SVP at Actinium Pharmaceuticals?
Actinium Pharmaceuticals appointed Sean Maenpaa as Senior Vice President of Business Development, effective October 12, 2026. He brings over two decades of oncology and radiopharmaceutical experience to the position.
What are Sean Maenpaa's responsibilities at Actinium Pharmaceuticals?
Maenpaa will oversee Actinium's corporate development initiatives, including out-licensing, strategic partnerships, collaboration transactions, and in-licensing opportunities for the company's targeted radiotherapy pipeline.
Where did Sean Maenpaa work prior to joining Actinium?
Maenpaa previously held senior leadership and commercial roles at BWXT Medical, Telix Pharmaceuticals, Clovis Oncology, Bayer AG, Novartis, and Celgene, and worked as Managing Director of Maenpaa Consulting LLC.